AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00409994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: dosis escalation: 2/4/6 mg rapamycin tablets, once daily during 13 days
Study NCT06765577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Finger Blood Pressure Measurement
Description: Finger Blood Pressure Measurement were taken from three digits: the thumb (F1), the middle finger (F2), and the little finger (F3) from both arms.
Study NCT02408289 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Epicatechin
Description: Low-flavonoid cocoa powder plus 1 mg epicatechin per kg of body weight will be consumed as a beverage
Study NCT02408289 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Procyanidins
Description: Low-flavonoid cocoa powder plus 3.7 mg procyanidins per kg of body weight will be consumed as a beverage.
Study NCT04375254 — intervention group
Intervention type: OTHER
Intervention: NbB psychopharmacology training
Description: a two part course in psychopharmacology based on Neuroscience based Nomenclature
Study NCT01689480 — intervention group
Intervention type: OTHER
Intervention: FSHD training
Description: The training will consist in 3 sessions of 35 min of training per week at home on an ergocycle. The training will be divided in (i) 2 sessions of 30 min aerobic exercises at a constant but moderate (60% of maximal aerobic power, MAP) intensity followed with 5 sets of 10 revolutions at near-maximal intensity and (ii) an interval-training session. This latter session will consist in 5 min warm-up at 40% MAP followed by 5 times 1 min at 80% MAP (recovery = 4 min at 40% MAP) followed by 5 min of active recovery. A systematic supervision of the sessions by the coach will be performed by phone, by using the heart rate recordings and values of Analogic Visual Scale for pain and fatigue.
Study NCT02631928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human biphasic insulin
Description: investigational insulin, biosimilar human insulin suspension of 30% normal insulin and 70% basal protamined insulin
Study NCT02631928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human biphasic insulin, reference
Description: marketed product, human insulin suspension of 30% normal insulin and 70% basal (NPH) insulin
Study NCT03646214 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Midline traction oral appliance
Description: Device positions the mandible forward to open airway; device can be titrated to gradually advance the mandible.
Study NCT05674123 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Undergo colonoscopy
Study NCT05674123 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound
Description: Undergo rectal endoscopic ultrasound
Study NCT05674123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Ancillary studies
Study NCT05674123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Undergo resection with the Flex Robotic System
Study NCT05674123 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo resection with the Flex Robotic System
Study NCT02693106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: Visit corresponding to a standardize breakfast taken alone (control visit) followed by a period of 4-hour with multiple blood sampling.
Study NCT02693106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine
Description: Visit corresponding to a standardize breakfast with 5 g of leucine followed by a period of 4-hour with multiple blood sampling.
Study NCT02693106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Butyrate -
Description: Visit corresponding to a standardize breakfast with 3.6 g of butyrate followed by a period of 4-hour with multiple blood sampling.
Study NCT02693106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Butyrate +
Description: Visit corresponding to a standardize breakfast with 7.2 g of butyrate followed by a period of 4-hour with multiple blood sampling.
Study NCT02693106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Octanoate -
Description: Visit corresponding to a standardize breakfast with 5 g of octanoate followed by a period of 4-hour with multiple blood sampling.
Study NCT02693106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Octanoate +
Description: Visit corresponding to a standardize breakfast with 10 g of octanoate followed by a period of 4-hour with multiple blood sampling.
Study NCT02693106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carnitine
Description: Visit corresponding to a standardize breakfast with 1.95 g of carnitine followed by a period of 4-hour with multiple blood sampling.
Study NCT02693106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Butter fraction
Description: Visit corresponding to a standardize breakfast with 65 g of butter fraction followed by a period of 4-hour with multiple blood sampling.
Study NCT00160706 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol (CDP870)
Description: Liquid for subcutaneous injection, 200 mg/ml. 400 mg at Weeks 0, 2, 4 and thereafter every 4 weeks until Week 360.~Up to 84 months of therapy in this study.
Study NCT04231929 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chemoembolization
Description: First, an angiography of the celiac trunk, superior mesenteric artery and hepatic artery will be obtained by using a peripheral arterial approach.~Arterial embolization will be performed through catheterization of intrahepatic arteries, as selectively as possible (tumor feeders, subsegmental, segmental). The size of the microcatheter must be consistent with the size of BioPearl™ microspheres used. Microspheres of 200 µm will be be used. They will be loaded with the appropriate dose of doxorubicin injectable solution, mixed with the contrast media and distributed according to the location of the HCC lesions. The endpoint of the procedure will be achieved end when stasis of the feeders is achieved.
Study NCT02458768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVF-M HP Inj.
Study NCT02458768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menopur® Inj.
Study NCT02796066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Applied once a day
Study NCT02796066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSN2898
Description: Applied once a day
Study NCT01960270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: INTERSTIM II
Description: A second stimulator is implanted on controlateral site
Study NCT03418584 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HybridAPC
Description: HybridAPC is a device which combines submucosal fluid injection with APC
Study NCT04582058 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Health of lifestyle
Description: Mobile health of lifestyle with an orientation about daily activities and necessary care to patients with CEID, and protocol of exercise training with images and guidelines to execute five days per week, with a duration of 50 minutes, and space for doubts which patients could send message to researcher.
Study NCT00987870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFH772
Study NCT00987870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00987870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcipotriol/betamethasone
Study NCT02537236 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids
Description: Omega-3 fatty acid supplementation with fish oil.
Study NCT01115920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTP-131 (Bendavia™)
Description: Single 4 hour intravenous infusion
Study NCT00660933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose
Description: Iron sucrose 200 mg/day iv, (20 mg/ml) + 200 cc de NaCl 0,9%/day in 60 minutes per 2 days.
Study NCT00660933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: NaCl 0,9% 200 ml /day iv in 60 minutes per 2 days
Study NCT00623740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone
Description: Intravenous slow of hemisuccinate hydrocortisone 0.5 mg/kg/12 hours during 7 days then 0.5mg/kg/24 hours during 3 days.
Study NCT00623740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: intravenous slow of placebo 0.5mg/kg/12 hours during 7 days then 0.5 mg/kg/24 hours during 3 days
Study NCT02717416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endo-Clot
Description: After epinephine injection therapy, Endo-Clot is applied immediately onto the bleeding lesion. A total of 2 g of AMP® particle powder will be sprayed onto the bleeding lesion by a catheter inserted through a working channel of the endoscope under continuous air flow.
Study NCT02717416 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hemoclip or electrical coagulation
Description: After epinephrine injection therapy, hemoclip (HX-610-135, Olympus, Japan) will be applied onto the bleeding lesions. The number of hemoclip will be decided by endoscopist. Electrical coagulation will be applied onto the bleeding lesions.
Study NCT05937594 — intervention group
Intervention type: GENETIC
Intervention: Buccal swab saliva for further genetic testing
Description: Genetic testing. Whole saliva RNA will be isolated for downstream microRNA quantification.
Study NCT04225598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAM2038
Description: Patients will receive a 24 mg dose of injectable CAM2038 in the ED on Day 0.
Study NCT04225598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine Sublingual Product
Description: COWS ≥ 8: Patients will receive 4mg of SL-BUP for a COWS score of 8-12 (mild withdrawal). After 30-45 minutes if tolerated and no unanticipated adverse reactions, an additional 4mg can be administered for a total of 8mg in the ED. Patients presenting with moderate-severe withdrawal (COWS >≥ 13) will receive an initial dose of 8mg SL-BUP. All patients will receive a buprenorphine prescription and instructions for additional BUP doses to allow for up to a dose of 12mg if needed, and for 16mg each subsequent day until their scheduled follow up appointment for ongoing MOUD (medications for opioid use disorder).~COWS 4-7: Patients will be provided with a uniform set of instructions to guide unobserved (home) induction. They will be prescribed doses of SL-BUP to allow them to take dose up to 12mg in the 24 hours after discharge. All patients will also receive a buprenorphine prescription for 16mg each subsequent day until their scheduled follow up appointment for ongoing MOUD.
Study NCT05134337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-305
Description: Oral LOXO-305
Study NCT05134337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral itraconazole
Study NCT05134337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Oral rifampin
Study NCT02843802 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryosurgery
Description: Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
Study NCT02843802 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
Study NCT02843802 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK Immunotherapy
Description: Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
Study NCT02080182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcysteine
Study NCT02080182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo acetylcysteine
Study NCT05432908 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Orofacial exercises and oropharyngeal functions
Description: Oropharyngeal exercises (derived from speech-language pathology) to the tongue and facial muscles exercises as well stomatognathic functions.
Study NCT02775318 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stellate Ganglion Block
Description: Under aseptic conditions, transducer is placed on the surface of the neck at the level of C6 vertebrae. The internal jugular vein, carotid artery, thyroid gland, trachea, C6 vertebrae, transverse process of C6, esophagus , longus colli with its covering prevertebral fascia and esophagus are visualized. A 25-gauge Quincke spinal needle was inserted paratracheal towards the middle of the longus colli muscle. The endpoint of the injection was the ultrasound image of the tip of the needle as it penetrates the prevertebral fascia covering the longus colli muscle. The drug is then injected and spread of drug is visualized in real time.
Study NCT02775318 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine
Description: 10 ml of 0.5% injection bupivacaine is used for giving stellate ganglion block on the side of cerebral vasospasm
Study NCT02775318 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transcranial Doppler
Description: The principle on which the TCD works is that with arterial narrowing, the blood flow velocity within the vessel increases. A good correlation has been found between the TCD blood flow velocities and vasospasm. The MCA velocity greater than 120 cm/sec indicates mild vasospasm , velocity greater than 130 cm/sec indicates moderate vasospasm and velocity greater than 200 cm/sec indicates severe vasospasm.
Study NCT02775318 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Digital Subtraction Angiography
Description: Digital subtraction angiography is a direct method for the assessment of vessel caliber. It generates high resolution, high contrast and low artifact images using digital subtraction technology. Direct visualization using DSA is the gold standard for the radiographic diagnosis of cerebral vasospasm
Study NCT00949884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil
Description: Oral tablets, once daily, at either 20mg or 40mg daily.
Study NCT00949884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: olmesartan medoxomil
Description: Oral tablets, once daily, at either 20mg or 40mg daily.
Study NCT00949884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo oral tablets once daily for two weeks
Study NCT00949884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan potassium
Description: losartan potassium oral tablet at either 50mg or 100 mg daily dose.
Study NCT03578614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: 3 physical activity sessions are planned by week, 2 supervised and 1 non-supervised conducted over 6 months. On the first 2 months, the supervised sessions have 10 minutes of warm-up + 5 minutes active pause (balance, agility and coordinative exercises) + 15 minutes walking + 5 minutes active pause (resistance exercises - 1 series of 12 repetitions~- 3 callisthenic exercises) + 15 minutes walking + 5 minutes flexibility (1 series of 10 seconds in 3 different postures). The aimed intensity in these first two months is 12/13. Between the 2nd and the 4th months, the duration of the walking period increases, as well as the intensity, RPE 13/14. Between the 4th and the 6th months, again the duration of the walking period increases, as well as the intensity, RPE 14/15. To measure the intensity level of the physical activity, the Borg Rating of Perceived Exertion (RPE) ranging from 6 (rest) to 20 (maximum effort) is used.
Study NCT02949921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiesse injectable implant and 2% lidocaine HCL
Description: Radiesse injectable implant injected in small boluses (0.2-0.5cc/bolus). No more than 0.5cc per bolus. No more than 3 cc (2 syringes) will be injected per hand.
Study NCT01835262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine: 0.1 mg /kg given as IVP
Study NCT01835262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine:0.3 mg/given as IVP
Study NCT02537236 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: TLC nutritional intervention
Description: nutritional orientation.
Study NCT04435171 — intervention group
Intervention type: PROCEDURE
Intervention: Renal transplantation
Description: Open or robot assisted renal transplantation
Study NCT02293395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Description: ASA 100 mg enteric-coated tablet once daily orally.
Study NCT02537236 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation with fish oil and TLC nutritional intervention.
Description: Omega 3 fatty acid supplementation with fish oil and nutritional counseling of TLC diet.
Study NCT02293395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 2.5 mg tablet twice daily orally.
Study NCT02293395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg once daily orally.
Study NCT02293395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 75 mg once daily orally.
Study NCT02473588 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Retia Medical Long Time Interval Analysis
Description: Retia Medical Long Time Interval Analysis will be used to analyze the blood pressure tracing of patients having surgery who have an arterial catheter
Study NCT01444547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel and cisplatin
Description: Paclitaxel 150 mg/m2 will be administered as an intravenous (IV) infusion over 3 hour on Days 1; Cisplatin 50 mg/m2 will be administered as an intravenous (IV) infusion on Days 2, and to take enough hydration in the day and the next day.~14 days as a cycle, up to 8 cycles.
Study NCT04686370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laser treated implant surface
Description: Better marginal bone stability is expected for this type
Study NCT04686370 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laser treated implant surface
Description: Better marginal bone stability is expected for this type
Study NCT03845335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dental implant-supported restoration
Description: During the oral surgery session for dental implant insertion, after implant site preparation, the opaque sealed envelope containing the patient allocation will be opened. Following the group allocation, the patient will receive either an HA-coated Hybrid or moderately rough dental implant
Study NCT03845335 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dental implant-supported restoration
Description: During the oral surgery session for dental implant insertion, after implant site preparation, the opaque sealed envelope containing the patient allocation will be opened. Following the group allocation, the patient will receive either an HA-coated Hybrid or moderately rough dental implant
Study NCT02396550 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Expectations
Description: Give positive expectation of the treatment efficacy to patients
Study NCT02396550 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mobilization with movement
Description: Give neutral expectation of the treatment efficacy to patients
Study NCT02373605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling,Thrust Manipulation
Description: HVLA thrust manipulation to upper cervical and upper thoracic regions. Dry needling to cervicothoracic and craniofacial regions. Up to 8 treatment sessions over 4 weeks.
Study NCT02373605 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise,Non-thrust Mobilization
Description: Non-thrust mobilization and exercise to upper cervical and upper thoracic regions. Up to 8 treatment sessions over 4 weeks.
Study NCT01038401 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: GI endoscopy and GALT biopsies
Description: This project aims to characterize the residual replication of HIV-1 in subjects on HAART, particularly in the gut-associated lymphoid tissue (GALT)
Study NCT02293395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor 90 mg twice daily orally.
Study NCT02293395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 90 mg twice daily orally.
Study NCT00949715 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic or Vitatron Dual-Chamber Pacemaker
Description: A Medtronic or Vitatron market-approved dual-chamber implantable pulse generator (IPG) with atrial tachycardia/atrial fibrillation (AT/AF) trending ability
Study NCT00949715 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic SelectSecure 3830 Lead
Description: Medtronic market-approved SelectSecure Model 3830 bipolar pacing lead
Study NCT03361891 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WalkMORE Group
Description: Hospitalized Internal Medicine patients will walk with trained volunteer coaches twice daily until hospital discharge